Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

96 Well Microplates with 3D Epoxy Surface

Published: Monday, August 12, 2013
Last Updated: Monday, August 12, 2013
Bookmark and Share
Ideal platform for covalent binding of biomolecules.

Greiner Bio-One has developed 96 well microplates with a 3D epoxy surface in collaboration with its longstanding cooperation partner PolyAn.

The 3D epoxy surface is the ideal platform for covalent binding of proteins, peptides, DNA and oligonucleotides.

The three-dimensional functional matrix allows the development of covalent binding of nucleophiles to the plate surface without complex coupling chemistry.

The structure of the matrix, which has a thickness of up to 50 nm, also reduces unspecific binding to a minimum.

The three-dimensional epoxy 96 well microplates are used mainly if adsorptive binding of peptides or oligonucleotides, for example, to high/medium binding surfaces is ineffective or the binding strength is not sufficient.

Areas of application include detection methods such as ELISA, ELI-Spot, protein and peptide arrays and DNA binding.

The 3D epoxy surface is chemically and mechanically highly robust and features particularly homogeneous surface functionalisation.

The microplates with a 3D epoxy surface are free of detectable DNases and RNases. The shelf life at room temperature is two years.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Big Plans and 40 Years of Experience
Rudi Vollmer becomes new Technical Managing Director of Greiner Bio-One GmbH, responsible for production and technology.
Tuesday, June 30, 2015
Tradition Meets Innovation -­ Greiner Bio-One Celebrates 50 Successful Years
Company now has over 1,700 employees spread across seven production facilities.
Friday, December 13, 2013
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!